Article
Oncology
Kostandinos Sideras, David W. Hillman, Karthik Giridhar, Brenda F. Ginos, Richard C. Tenglin, Heshan Liu, Beiyun Chen, Winston Tan, Gerald G. Gross, Rex B. Mowat, Amylou C. Dueck, Edith A. Perez, Alvaro Moreno-Aspitia
Summary: Pixantrone showed insufficient activity in refractory HER2-negative MBC patients but appeared to have limited cardiotoxicity. The study was terminated.
Article
Pathology
Ankur Pandita, Matias Ekstrand, Sara Bjursten, Zhiyuan Zhao, Per Fogelstrand, Kristell Le Gal, Lars Ny, Martin O. Bergo, Joakim Karlsson, Jonas A. Nilsson, Levent M. Akyurek, Malin C. Levin, Jan Boren, Andrew J. Ewald, Keith E. Mostov, Max Levin
Summary: Intussusceptive angiogenesis, characterized by intravascular pillars, may play a role in the growth of human melanoma metastases. Inhibition of matrix metalloproteinase 9 (MMP9) could potentially block pillar formation and serve as a promising anti-angiogenic drug target for metastatic melanoma.
AMERICAN JOURNAL OF PATHOLOGY
(2021)
Article
Oncology
Meredith S. Pelster, Stephen K. Gruschkus, Roland Bassett, Dan S. Gombos, Michael Shephard, Liberty Posada, Maura S. Glover, Rinata Simien, Adi Diab, Patrick Hwu, Brett W. Carter, Sapna P. Patel
Summary: The combination regimen of nivolumab plus ipilimumab shows activity in metastatic uveal melanoma, yielding deep and sustained confirmed responses.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Harry H. Yoon, Fang-Shu Ou, Gamini S. Soori, Qian Shi, Dennis A. Wigle, Robert P. Sticca, Robert Clell Miller, James L. Leenstra, Patrick J. Peller, Brenda Ginos, Erica Heying, Tsung-Teh Wu, Timothy F. Drevyanko, Stephen Ko, Bassam Ibrahim Mattar, Daniel A. Nikcevich, Robert J. Behrens, Maged F. Khalil, George P. Kim, Steven R. Alberts
Summary: The trial reported that adding induction chemotherapy prior to trimodality therapy did not improve the primary endpoint of pathologic complete response (pathCR) in patients with oesophageal or gastrooesophageal junction adenocarcinoma. However, induction chemotherapy was associated with longer median overall survival (OS) and disease-free survival (DFS), particularly among patients with well/moderately differentiated tumors. These findings may guide further development of curative-intent trials in this disease.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Siren Morken, Seppo W. Langer, Anna Sundlov, Lene Weber Vestermark, Morten Ladekarl, Geir Olav Hjortland, Johanna B. Svensson, Elizaveta Mitkina Tabaksblat, Torjan Magne Haslerud, Jorg Assmus, Sonke Detlefsen, Anne Couvelard, Aurel Perren, Halfdan Sorbye
Summary: This study evaluated the efficacy and safety of everolimus and temozolomide as first-line treatment for metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms. The results showed that this treatment option can effectively control the disease and prolong progression-free survival and overall survival. The treatment response was better in NET G3 patients, but there were some toxicities reported.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Adi Diab, Scott S. Tykodi, Gregory A. Daniels, Michele Maio, Brendan D. Curti, Karl D. Lewis, Sekwon Jang, Ewa Kalinka, Igor Puzanov, Alexander Spira, Daniel C. Cho, Shanhong Guan, Erika Puente, Tuan Nguyen, Ute Hoch, Sue L. Currie, Wei Lin, Mary A. Tagliaferri, Jonathan Zalevsky, Mario Sznol, Michael E. Hurwitz
Summary: This study found that the combination of BEMPEG and NIVO showed promising antitumor activity in first-line metastatic melanoma, including extended median progression-free survival. Early on-treatment blood biomarkers were associated with treatment response.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Eric Zhuang, Edward Uchio, Michael Lilly, Xiaolin Zi, John P. Fruehauf
Summary: Docetaxel plus lycopene therapy showed effectiveness in advanced castrate resistant adenocarcinoma of prostate, with a 76.9% PSA response rate and a median survival of 35.1 months, indicating the potential value of this combination therapy.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Oncology
Saranya Chumsri, Zhuo Li, Daniel J. Serie, Nadine Norton, Afshin Mashadi-Hossein, Kathleen Tenner, Heather Ann Brauer, Sarah Warren, Patrick Danaher, Gerardo Colon-Otero, Ann H. Partridge, Lisa A. Carey, Florentine Hilbers, Veerle Van Dooren, Eileen Holmes, Serena Di Cosimo, Olena Werner, Jens Bodo Huober, Amylou C. Dueck, Christos Sotiriou, Cristina Saura, Alvaro Moreno-Aspitia, Keith L. Knutson, Edith A. Perez, E. Aubrey Thompson
Summary: This study identified a novel adaptive immune signature (AIS) that is significantly associated with improved outcomes in breast cancer patients treated with trastuzumab. AIS-low patients have poor outcomes despite receiving trastuzumab, but benefit from an addition of lapatinib.
Article
Oncology
Srivandana Akshintala, Nicole C. Mallory, Yao Lu, Karla Ballman, Scott M. Schuetze, Rashmi Chugh, Robert G. Maki, Denise K. Reinke, Brigitte C. Widemann, Ae Rang Kim
Summary: This study analyzes the outcomes of patients with malignant peripheral nerve sheath tumors enrolled on phase II trials conducted by SARC and evaluates the effect of enrollment characteristics on progression-free survival. The results provide a historical baseline for future clinical trials in patients with MPNST.
Editorial Material
Ophthalmology
Jerome Chartier, Pierre-Jean Pisella, Raoul Kanav Khanna
Summary: This case report presents a rare occurrence of cutaneous malignant melanoma metastasizing to the intraocular lens.
JAMA OPHTHALMOLOGY
(2021)
Article
Oncology
Araba A. Adjei, Camden L. Lopez, Daniel J. Schaid, Jeff A. Sloan, Jennifer G. Le-Rademacher, Charles L. Loprinzi, Aaron D. Norman, Janet E. Olson, Fergus J. Couch, Andreas S. Beutler, Celine M. Vachon, Kathryn J. Ruddy
Summary: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and potentially permanent complication of treatment with taxanes and platinum-based compounds. A genome-wide association study identified genetic variants near PDE6C and TMEM150C that were associated with CIPN in different study populations, but lack of replication suggests uncertainty in their strong association with CIPN.
Article
Oncology
Gang Guo, Liangyou Gu, Xu Zhang
Summary: Everolimus, an mTOR inhibitor, showed efficacy for patients with invasive malignant renal EAML, with better responses observed in patients with TSC. Treatment led to a significant decrease in tumor diameter post-treatment.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Min Zhu, Da-Ya Zhang, Guan-Jun Zhang, Zhan-Bo Wang, Ming-Yang Lid
Summary: Melanoma, a malignant form of skin cancer, often results in misdiagnosis when it metastasizes to the gastrointestinal tract. This study reports a case of a 36-year-old male initially diagnosed with gastric cancer, which was later confirmed as amelanotic melanoma metastasis. Therefore, pathological examination is necessary when amelanotic neoplasms are observed during gastroscopy in patients with a history of melanoma.
Article
Oncology
Stefanie Meyer, Diana Handke, Anja Mueller, Katharina Biehl, Markus Kreuz, Juergen Bukur, Ulrike Koehl, Maria-Filothei Lazaridou, Mark Berneburg, Andre Steven, Chiara Massa, Barbara Seliger
Summary: Limited knowledge exists about the molecular processes controlling HLA class II APM components in melanoma. This study found heterogeneous basal expression of HLA class II antigens and components in melanoma cells is caused by distinct molecular mechanisms and has clinical relevance.
Article
Medicine, General & Internal
Alexandru-Rares Stoian, Gabriela Rahnea-Nita, Anda-Natalia Ciuhu, Laurentia Gales, Rodica-Maricela Anghel, Laura-Florentina Rebegea, Roxana-Andreea Rahnea-Nita, Liliana-Florina Andronache, Ioana Soare, Gabriela Stoleriu
Summary: The treatment of malignant melanoma is an extensively studied field, with factors such as timing, sequencing, and adverse event management playing crucial roles in therapeutic decisions. A case study of a patient diagnosed with metastatic malignant melanoma reveals the importance of comprehensive response evaluation and the occurrence of specific prognostic factors. The early and accurate diagnosis of adverse events in new therapies demands a multidisciplinary approach, as it greatly affects therapeutic decisions.